Syntara Ltd (ASX: SNT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Syntara Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$57.16 million
P/E Ratio
4.64
Dividend Yield
0.00%
Shares Outstanding
1.63 billion
Earnings per share
-0.008
Dividend per share
N/A
Year To Date Return
-2.86%
Earnings Yield
21.54%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Syntara Ltd (ASX: SNT)
Latest News
⏸️ Investing
The big reason why Pharmaxis Ltd shares slumped today
⏸️ Investing
Here's why Bionomics Ltd shares soared today
⏸️ Investing
Could these 4 bruised biotech stocks be about to recover?
❮2
SNT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Syntara Ltd
Pharmaxis Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. Its respiratory products include bronchitol and aridol. The company was founded by Brett Charlton and William B. Cowden on May 29, 1998 and is headquartered in Sydney, Australia.
SNT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 05 Feb 2026 | $0.03 | $0.00 | 0.00% | 332,824 | $0.03 | $0.03 | $0.03 |
| 04 Feb 2026 | $0.03 | $0.00 | 0.00% | 1,201,967 | $0.04 | $0.04 | $0.03 |
| 03 Feb 2026 | $0.04 | $0.01 | 33.33% | 1,901,127 | $0.03 | $0.04 | $0.03 |
| 02 Feb 2026 | $0.03 | $0.00 | 0.00% | 814,587 | $0.03 | $0.03 | $0.03 |
| 30 Jan 2026 | $0.03 | $0.00 | 0.00% | 629,754 | $0.03 | $0.03 | $0.03 |
| 29 Jan 2026 | $0.03 | $0.00 | 0.00% | 2,223,143 | $0.04 | $0.04 | $0.03 |
| 28 Jan 2026 | $0.03 | $0.00 | 0.00% | 1,041,132 | $0.04 | $0.04 | $0.03 |
| 27 Jan 2026 | $0.04 | $0.00 | 0.00% | 982,094 | $0.04 | $0.04 | $0.04 |
| 23 Jan 2026 | $0.04 | $0.00 | 0.00% | 952,584 | $0.04 | $0.04 | $0.03 |
| 22 Jan 2026 | $0.03 | $0.00 | 0.00% | 191,938 | $0.04 | $0.04 | $0.03 |
| 21 Jan 2026 | $0.03 | $0.00 | 0.00% | 1,012,316 | $0.03 | $0.04 | $0.03 |
| 20 Jan 2026 | $0.03 | $0.00 | 0.00% | 637,960 | $0.03 | $0.04 | $0.03 |
| 19 Jan 2026 | $0.03 | $0.00 | 0.00% | 263,152 | $0.04 | $0.04 | $0.03 |
| 16 Jan 2026 | $0.04 | $0.00 | 0.00% | 127,445 | $0.04 | $0.04 | $0.03 |
| 15 Jan 2026 | $0.04 | $0.00 | 0.00% | 987,615 | $0.03 | $0.04 | $0.03 |
| 14 Jan 2026 | $0.03 | $0.00 | 0.00% | 1,823,187 | $0.03 | $0.04 | $0.03 |
| 13 Jan 2026 | $0.03 | $0.00 | 0.00% | 902,003 | $0.03 | $0.03 | $0.03 |
| 12 Jan 2026 | $0.03 | $0.00 | 0.00% | 492,035 | $0.03 | $0.03 | $0.03 |
| 09 Jan 2026 | $0.03 | $0.00 | 0.00% | 375,669 | $0.03 | $0.03 | $0.03 |
| 08 Jan 2026 | $0.03 | $0.00 | 0.00% | 1,296,616 | $0.03 | $0.03 | $0.03 |
| 07 Jan 2026 | $0.03 | $0.00 | 0.00% | 728,263 | $0.03 | $0.03 | $0.03 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 24 Nov 2025 | Gary Phillips | Issued | 4,769,177 | $143,075 |
Issue of options.
|
| 24 Nov 2025 | Gary Phillips | Issued | 881,465 | $26,443 |
Director remuneration.
|
| 24 Nov 2025 | Kathleen Metters | Issued | 3,000,000 | $90,000 |
Issue of options.
|
| 20 Feb 2025 | Waradana De Silva | Issued | 9,753,442 | $585,206 |
Placement.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Gary Phillips | Chief Executive OfficerManaging Director | Mar 2013 |
Mr Phillips has 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia. From 1994 to 1998, he was Chief Executive Officer at Ciba Geigy in Hungary (Merged to form Novartis in 1996). After a period of 3 years as an Area Manager for Novartis responsible for 9 countries in Asia Pacific in 2001 he joined Novartis Australia as Group Company Head and Chief Executive Officer of its Pharmaceutical Division.
|
| Dr Simon Green | Non-Executive Director | Dec 2022 |
Dr Green is a senior global pharma executive with 30 years of experience in the biotechnology industry focused on the discovery, development and commercialization of life-saving medicines. Simon was a non-executive director of Acrux Pty Ltd (2016 -2019) and is currently a non-executive director of Clover Corporation Ltd and co-founder and CEO of lmmunosis Pty Ltd, a start-up diagnostic company.
|
| Dr Kathleen Mary Metters | Non-Executive DirectorNon-Executive Chairman | Jun 2017 |
Dr Metters has 25 years of experience in the discovery and development of novel therapies for the treatment of serious diseases. She is currently working as an independent biopharma consultant and board member. From 2011-2014 she was President and Chief Executive officer for Lycera Corp., a biopharmaceutical company pioneering innovative approaches to novel oral medicines for treatment of autoimmune diseases and cancer. From 1988 to 2011 she was employed by Merck & Co in various roles.
|
| Mr Waradana Malitha Hashan De Silva | Non-Executive Director | Jan 2023 |
Mr De Silva is a life sciences investment professional with knowledge of the biotech, pharmaceutical and medical technology sectors. His previous roles include associate healthcare analyst at Macquarie Group covering ASX-listed healthcare companies and lead healthcare analyst at CLSA Australia. Prior to moving into life science investment, he worked at Eli Lilly in various roles focused on the commercialization of new and existing pharmaceuticals.
|
| Mr Tim Luscombe | Company Secretary | Jan 2026 |
-
|
| David McGarvey | Chief Financial Officer and Company Secretary |
-
|
|
| Jana Baskar | Chief Medical Officer |
-
|
|
| Tim Luscombe | Company Secretary |
-
|
|
| Wolfgang Jarolimek | Head of Drug Discovery |
-
|
|
| Kristen Morgan | Head of Medical and Regulatory Affairs |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| D & A Holdings Limited | 296,159,707 | 18.23% |
| HSBC Custody Nominees (Australia) Limited | 170,900,818 | 10.52% |
| Amal Security Services Pty Ltd Kp Rx Healthcare A/C | 63,324,871 | 3.90% |
| Citicorp Nominees Pty Limited | 59,469,618 | 3.66% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 58,956,329 | 3.63% |
| Moore Family Nominee Pty Ltd Moore Family Super Fund A/C | 33,043,678 | 2.03% |
| BNP Paribas Noms Pty Ltd | 30,887,463 | 1.90% |
| J P Morgan Nominees Australia Pty Limited | 30,856,967 | 1.90% |
| Hb Biotechnology Ltd | 23,679,103 | 1.46% |
| BNP Paribas Nominees Pty Ltd Ib Au Noms Retailclient | 14,419,515 | 0.89% |
| Agati Pty Ltd | 12,603,000 | 0.78% |
| Dr Toby David Cohen | 11,049,457 | 0.68% |
| Harper Bernays Limited Hb Biotechnology No 1 A/C | 10,586,067 | 0.65% |
| Mrs Anica Merle Maguire | 10,384,385 | 0.64% |
| Lawn Views Pty Ltd Angela Williams Family A/C | 9,714,602 | 0.60% |
| Rbo Pty Ltd | 9,000,000 | 0.55% |
| Kevrex Pty Ltd Kevrex Investment A/C | 8,000,000 | 0.49% |
| Mr David Seeman | 6,897,575 | 0.42% |
| Da&Djburt Pty Ltd | 6,324,529 | 0.39% |
| Souttar Superannuation Pty Ltd Rjs & Je Greenslade S/F A/C | 6,202,690 | 0.38% |
